Charles J. Ryan MD

Oncology•Middletown, NJ

Genitourinary Oncology, Hematologic Oncology

Member and Attending Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center

Join to View Full Profile

480 Red Hill RoadMiddletown, NJ 07748

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1996 - 2000
University of Wisconsin School of Medicine & Public HealthClass of 1996

Certifications & Licensure

CA State Medical License 2003 - 2026
NY State Medical License 2000 - 2026
NJ State Medical License 2024 - 2025
MN State Medical License 2018 - 2023

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy Start of enrollment: 2004 Apr 01
Completed
Phase 2
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer Start of enrollment: 2005 Jun 01
Terminated
Phase 1
Sorafenib and RAD001 Renal Cell Carcinoma Start of enrollment: 2006 Oct 01
Completed
Phase 1
Sandostatin for Patients With Androgen Independent Prostate Cancer Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Ketoconazole and Dexamethasone in Prostate Cancer Start of enrollment: 2009 Dec 11
Completed
Phase 2
Abiraterone Post Ketoconazole for Prostate Cancer Start of enrollment: 2010 Sep 10
Completed
Phase 2
Neoadjuvant BKM120 in High-risk Prostate Cancer Start of enrollment: 2013 Apr 23
Terminated
Phase 2
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2013 Jan 31
Terminated
Phase 1, Phase 2
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2014 Sep 02
Terminated
Phase 2
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Start of enrollment: 2021 Aug 17
RECRUITING
PHASE2
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)
ACTIVE_NOT_RECRUITING
NA
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.
John R Lozada, Andrew Elliott, Mark G Evans, James Wacker, Kathleen M Storey
Cancer Research Communications. 2025-02-01
11 citations
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi
European Urology. 2025-02-01
What's in a Name? Why Words Matter in Advanced Prostate Cancer.
William K Oh, Neeraj Agarwal, Alan Bryce, Pedro Barata, Courtney Bugler
European Urology. 2025-02-01

Lectures

Considerations for Systemic Therapy in Optimal Management of Oligometastatic Disease
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Other

Castrate resistant prostate cancer: Treatments targeting the androgen pathway
Ryan CJ, Dawson NA
http://www.uptodate.com/contents/castrate-resistant-prostate-cancer-treatments-targeting-the-androge
UpToDate, Wolters Kluwer Health - 2013-02-21

Press Mentions

What to Know About Complementary Therapies for Prostate CancerDecember 13th, 2024
Successes and Setbacks in Prostate Cancer Care: Seeking the Right Treatment for the Right Patient at the Right TimeJuly 23rd, 2024
The Prostate Cancer Foundation Launches ‘Black Men: Know Your Risk’ Campaign and Teams up with Atlanta Hawks for ‘Black History Month Assist Challenge’ to Raise Awareness and Funds for Prostate Cancer ResearchFebruary 1st, 2023
Join now to see all